Home > > > > > Report Detail

Hepatitis A - Epidemiology Forecast to 2028

Publisher Name :
Date: 15-Jan-2019
No. of pages: 50
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Hepatitis A - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Hepatitis A epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered

- United States

- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

- Japan

Study Period: 2016-2028

Hepatitis A Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Hepatitis A in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders' views are also taken into account to provide a deep understanding of the Hepatitis A outlook. It also includes the explanation of changing trends of epidemiology outlining the Hepatitis A scenario.

Hepatitis A Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Hepatitis A thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope

- The report covers detailed overview of Hepatitis A explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

- It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan

- The Hepatitis A Report assesses the disease risk and burden and highlights the unmet needs

- It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

- 10 Year Forecast

- 7MM Coverage

- Total Cases in Hepatitis A

Key assessments

- Patient Segmentation in Hepatitis A

- Hepatitis A Risk & Burden

- Factors driving growth in a specific Hepatitis A patient population

Hepatitis A - Epidemiology Forecast to 2028

Table of Contents

1. Report Introduction
2. Hepatitis A Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Hepatitis A in 2016
2.2. Patient Share Distribution of Hepatitis A in 2028
3. Disease Background and Overview: Hepatitis A
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Hepatitis A in 7MM
4.3. Total Prevalent/ Incident Patient Population of Hepatitis A in 7MM - By Countries
5. Epidemiology of Hepatitis A by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Hepatitis A
5.1.3. Sub-Type Specific cases of the Hepatitis A *
5.1.4. Sex- Specific Cases of the Hepatitis A *
5.1.5. Diagnosed Cases of the Hepatitis A
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Hepatitis A
5.4.3. Sub-Type Specific cases of the Hepatitis A *
5.4.4. Sex- Specific Cases of the Hepatitis A *
5.4.5. Diagnosed Cases of the Hepatitis A
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Hepatitis A
5.5.3. Sub-Type Specific cases of the Hepatitis A *
5.5.4. Sex- Specific Cases of the Hepatitis A *
5.5.5. Diagnosed Cases of the Hepatitis A
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Hepatitis A
5.6.3. Sub-Type Specific cases of the Hepatitis A *
5.6.4. Sex- Specific Cases of the Hepatitis A *
5.6.5. Diagnosed Cases of the Hepatitis A
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Hepatitis A
5.7.3. Sub-Type Specific cases of the Hepatitis A *
5.7.4. Sex- Specific Cases of the Hepatitis A *
5.7.5. Diagnosed Cases of the Hepatitis A
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Hepatitis A
5.8.3. Sub-Type Specific cases of the Hepatitis A *
5.8.4. Sex- Specific Cases of the Hepatitis A *
5.8.5. Diagnosed Cases of the Hepatitis A
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Hepatitis A
5.9.3. Sub-Type Specific cases of the Hepatitis A *
5.9.4. Sex- Specific Cases of the Hepatitis A *
5.9.5. Diagnosed Cases of the Hepatitis A
6. Unmet Needs of the Hepatitis A
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Hepatitis A in 7MM
Table 2: Total Prevalent/Incident Cases of the Hepatitis A in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Hepatitis A in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Hepatitis A in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Hepatitis A in United States (2016-2028)*
Table 6: Diagnosed Cases of the Hepatitis A in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Hepatitis A in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Hepatitis A in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Hepatitis A in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Hepatitis A in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Hepatitis A in France (2016-2028)
Table 12: Sub-Type Specific cases of the Hepatitis A in France (2016-2028) *
Table 13: Sex- Specific Cases of the Hepatitis A in France (2016-2028) *
Table 14: Diagnosed Cases of the Hepatitis A in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Hepatitis A in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Hepatitis A in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Hepatitis A in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Hepatitis A in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Hepatitis A in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Hepatitis A in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Hepatitis A in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Hepatitis A in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Hepatitis A in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Hepatitis A in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Hepatitis A in UK (2016-2028) *
Table 26: Diagnosed Cases of the Hepatitis A in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Hepatitis A in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Hepatitis A in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Hepatitis A in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Hepatitis A in Japan (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Hepatitis A in 7MM
Figure 2: Total Prevalent/Incident Cases of the Hepatitis A in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Hepatitis A in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Hepatitis A in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Hepatitis A in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Hepatitis A in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Hepatitis A in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Hepatitis A in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Hepatitis A in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Hepatitis A in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Hepatitis A in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Hepatitis A in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Hepatitis A in France (2016-2028) *
Figure 14: Diagnosed Cases of the Hepatitis A in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Hepatitis A in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Hepatitis A in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Hepatitis A in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Hepatitis A in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Hepatitis A in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Hepatitis A in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Hepatitis A in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Hepatitis A in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Hepatitis A in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Hepatitis A in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Hepatitis A in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Hepatitis A in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Hepatitis A in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Hepatitis A in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Hepatitis A in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Hepatitis A in Japan (2016-2028)

  • Global Hepatitis A Vaccine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 89
    According to our LPI (LP Information) latest study, the global Hepatitis A Vaccine market size was valued at US$ 690.5 million in 2023. With growing demand in downstream market, the Hepatitis A Vaccine is forecast to a readjusted size of US$ 810.9 million by 2030 with a CAGR of 2.3% during review period. The research report highlights the growth potential of the global Hepatitis A Vaccine market. Hepatitis A Vaccine are expected to show stable growth in the future market. However, produc......
  • Global Human Hepatitis B Immunoglobulin Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 02-Jan-2024        Price: US 3380 Onwards        Pages: 127
    Market Overview of Global Human Hepatitis B Immunoglobulin market: According to our latest research, the global Human Hepatitis B Immunoglobulin market looks promising in the next 5 years. As of 2022, the global Human Hepatitis B Immunoglobulin market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensiv......
  • Global Hepatitis A Vaccine Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 85
    According to our (Global Info Research) latest study, the global Hepatitis A Vaccine market size was valued at USD 726.3 million in 2023 and is forecast to a readjusted size of USD 842.5 million by 2030 with a CAGR of 2.1% during review period. Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year. Two types of HAV vaccines are currentl......
  • Global Hepatitis A Vaccine Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 117
    Report Overview: Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year. Two types of HAV vaccines are currently available internationally: 1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available in paediatric dose (0.5 ml) for children aged 1 year to 15 ye......
  • Global Thymosin a1 Professional Survey Report 2023, Forecast to 2028
    Published: 15-Nov-2023        Price: US 3280 Onwards        Pages: 103
    Thymosin ?? is a peptide fragment derived from prothymosin alpha, a protein that in humans is encoded by the PTMA gene. It was the first of the peptides from Thymosin Fraction 5 to be completely sequenced and synthesized. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their ......
  • Global Thymosin a1 Market Research Report 2023, Forecast to 2028
    Published: 15-Nov-2023        Price: US 2680 Onwards        Pages: 136
    Thymosin ?? is a peptide fragment derived from prothymosin alpha, a protein that in humans is encoded by the PTMA gene. It was the first of the peptides from Thymosin Fraction 5 to be completely sequenced and synthesized. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their ......
  • Global Hepatitis B Immune Globulin Market Research Report 2023
    Published: 06-Nov-2023        Price: US 2900 Onwards        Pages: 85
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Hepatitis B Immune Globulin market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - ADMA Biologics - Bio Products Laboratory - Grifols - Biotest AG - CSL Behring - FFF Enterprises - Cleveland Clinic Seg......
  • Global Sofosbuvir Market Research Report 2023
    Published: 31-Oct-2023        Price: US 2900 Onwards        Pages: 94
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Sofosbuvir market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Teva Pharmaceutical Industries Ltd - DONG BANG FUTURE TECH & LIFE CO., LTD - Beaukev Pharma International Pvt.Ltd - DEAFARMA - Tecoland - Anhui HaiKang Pha......
  • Global Hepatitis A Vaccine Market Insights, Forecast to 2029
    Published: 22-Sep-2023        Price: US 4900 Onwards        Pages: 97
    Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year. Two types of HAV vaccines are currently available internationally: 1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available in paediatric dose (0.5 ml) for children aged 1 year to 15 years, and ......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs